Literature DB >> 23906296

Cell-cycle arrest at G2/M and proliferation inhibition by adenovirus-expressed mitofusin-2 gene in human colorectal cancer cell lines.

X Cheng, D Zhou, J Wei, J Lin.   

Abstract

The mitofusin-2 (Mfn2) is a novel gene characterised as a cell proliferation inhibitor. Mfn2 protein over-expression, mediated by an adenovirus, has a significant anti-proliferative effect in hepatoma carcinoma cells. However, there is no report on the effect of Mfn2 on colorectal cancer (CRC). In this study, we found that Mfn2 protein and mRNA levels were downregulated in CRC tissues compared to nearby normal tissues. An adenovirus encoding the complete Mfn2 open reading frame (Ad-Mfn2) exhibited a prominent anti-proliferative effect in the CRC cell lines HCT 116, HT-29, and SW480. Ad-Mfn2 infection significantly inhibited the proliferation of CRC cells compared with Ad-GFP infection. Mfn2 overexpression resulted in a cell-cycle arrest at G2/M phase in CRC cells, and it increased the levels of p-cdc2 (Tyr15) and Myt1; however, the levels of cyclin B1 and p-ERK1/2 was reduced. Mfn2 overexpression aslo increased the levels of active caspase-3 and cleaved PARP. Taken together, these findings indicate that Mfn2 has a significant anti-proliferative effect in CRC cells using adenoviral vectors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23906296     DOI: 10.4149/neo_2013_080

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  16 in total

Review 1.  Interplay of mitochondrial fission-fusion with cell cycle regulation: Possible impacts on stem cell and organismal aging.

Authors:  B Spurlock; Jma Tullet; J L Hartman; K Mitra
Journal:  Exp Gerontol       Date:  2020-03-24       Impact factor: 4.032

2.  Metabolic Stress and Disorders Related to Alterations in Mitochondrial Fission or Fusion.

Authors:  Mansi Babbar; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2013

3.  Mitofusin-2 is a novel anti-angiogenic factor in pancreatic cancer.

Authors:  Zhichuan Lin; Xiaoyi Lin; Jinhong Chen; Guoqiang Huang; Tangen Chen; Liling Zheng
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.

Authors:  Danchen Wu; Asish Dasgupta; Austin D Read; Rachel E T Bentley; Mehras Motamed; Kuang-Hueih Chen; Ruaa Al-Qazazi; Jeffrey D Mewburn; Kimberly J Dunham-Snary; Elahe Alizadeh; Lian Tian; Stephen L Archer
Journal:  Free Radic Biol Med       Date:  2021-01-12       Impact factor: 8.101

5.  Mitochondrial Fragmentation Due to Inhibition of Fusion Increases Cyclin B through Mitochondrial Superoxide Radicals.

Authors:  Tejas M Gupte
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

6.  Lentivirus vector-mediated mitofusin-2 overexpression in rat ovary changes endocrine function and promotes follicular development in vivo.

Authors:  Xiaojing Hu; Xiubing Lei; Jidong Wang; Hongjuan Pan; Cong Li; Zhenwei Yao
Journal:  Exp Ther Med       Date:  2014-07-09       Impact factor: 2.447

Review 7.  Mitofusin 2: from functions to disease.

Authors:  Riccardo Filadi; Diana Pendin; Paola Pizzo
Journal:  Cell Death Dis       Date:  2018-02-28       Impact factor: 8.469

8.  Mitochondrial Dynamics Related Genes -MFN1, MFN2 and DRP1 Polymorphisms are Associated with Risk of Lung Cancer.

Authors:  Xiaohua Liang; Shengqiang Dang
Journal:  Pharmgenomics Pers Med       Date:  2021-06-14

9.  PINK1-induced phosphorylation of mitofusin 2 at serine 442 causes its proteasomal degradation and promotes cell proliferation in lung cancer and pulmonary arterial hypertension.

Authors:  Asish Dasgupta; Kuang-Hueih Chen; Patricia D A Lima; Jeffrey Mewburn; Danchen Wu; Ruaa Al-Qazazi; Oliver Jones; Lian Tian; Francois Potus; Sebastien Bonnet; Stephen L Archer
Journal:  FASEB J       Date:  2021-08       Impact factor: 5.834

Review 10.  Mitochondrial Dynamics in Type 2 Diabetes and Cancer.

Authors:  Michelle Williams; M Cecilia Caino
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.